CopyRigh ©Shandong Aobo Biological Technology Co., Ltd.        鲁ICP备18004325号-1       Powered by


HOME                 PRODUCTS                 QUALITY                R&D                 NEWS                ABOUT                 SERVICE                CONTACT     





Page view:

Adhering to the cooperative concept of "mutual benefit and common development", the pharmaceutical industry research institute continues to expand the direction of cooperation.

In China, the pharmaceutical industry has successfully established R&D resource-complementary, cooperation and win-win partnerships with dozens of scientific research institutions and universities such as Nanjing University; Southeast University; Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Guangzhou Institute of Health, CAS; and Institute of Materia Medica, Chinese Academy of Medical Sciences; and also cooperates with the Shanghai Institute of Medical Technology, the Second Military Medical University, the Sichuan Antibiotic Research Institute and other scientific research institutions to jointly establish four joint laboratories. Overseas, the pharmaceutical industry has reached a cooperation agreement with Johnson & Johnson Pharmaceuticals, Advenchen, BioMarin, BiolineRx, Centaurus, etc., and will conduct international cooperation research in new drug screening, biopharmaceuticals, pharmaceutical preparations, etc. The pharmaceutical industry also has established cooperation with Karolinska Institute, Sweden and the University of Pennsylvania to further open up space for a wider range of international cooperation in the future.

Co-construction laboratory

After more than 30 years of development, the research institute currently has more than 800 independent research and development personnel specializing in chemical, biology, pharmaceutical, pharmacological, analytical, medical and other fields, and nearly 60% of them are doctors, masters and or have other senior technical titles. It has gradually formed three personnel talent teams including a doctoral innovation team, a senior engineer technical team and an expert academic team, who shoulder a series of important scientific research tasks such as new drug research and development and technological transformation in the pharmaceutical industry.